Targeting Latent HIV Infection. A Step Closer to the Treatment of HIV.
Antiretroviral therapy is prescribed to treat HIV infection. Although antiretroviral therapy has the impact of suppressing HIV levels in the blood, the virus continues to exist in long-lasting, latently infected resting CD4+ T cells.
The HIV latency is the greatest obstacle to obtaining a cure for HIV infection as these cells can persist despite decades of treatment with antiretroviral therapy. Without continuously taking the antiretroviral therapy, viral loads increase in the blood. Till now, there is no treatment available to target these latently infected CD4+ T cells.
On January 22,2020, unprecedented study published in the journal Nature developed a compound known as AZD5582 to activate latently infected CD4+ T cells, reversing the latency state. Researchers in this study found that AZD5582 showed very little or no toxicity, rendering it safe and suitable for use in the human body.
For the first time, a study proves that targeting latent HIV infection can occur. It is expected that this step will have great impact on treatment of HIV.
References
Comments
Post a Comment